G
Genmab A/S (GMAB)
NMS – Real vaqt narxi. Valyuta: USD
26.12
-0.02 (-0.08%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
25.80
-0.32 (-1.23%)
Bozordan keyin: Jun 26, 2026, 7:42 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
26.12
-0.02 (-0.08%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
25.80
-0.32 (-1.23%)
Bozordan keyin: Jun 26, 2026, 7:42 PM EDT
Genmab A/S, biotexnologiya kompaniyasi, Daniyada saraton va boshqa kasalliklarni davolash uchun antitelarga asoslangan mahsulotlar va mahsulot nomzodlarini ishlab chiqadi. Kompaniya EPKINLY va TEPKINLY ni kattalar bemorlarda qaytalangan yoki refrakter (R/R) diffuz katta B-hujayrali limfoma (DLBCL), katta B-hujayrali limfoma va follikulyar limfoma (FL) uchun; va Tivdak ni kimyoterapiya paytida yoki undan keyin kasallik rivojlangan takroriy/metastatik bachadon bo'yni saratoni bo'lgan kattalar bemorlar uchun sotadi. Shuningdek, u Epcoritamab ni R/R DLBCL va FL, birinchi qator DLBCL va FL, B-hujayrali non-Xochkin limfoma, R/R surunkali limfotsitar leykemiya va Richter sindromi, hamda bolalarda agressiv etuk B-hujayrali neoplazmalar uchun; tisotumab vedotin ni qattiq o'smalar uchun; Acasunlimab ni qattiq o'smalar va kichik hujayrali bo'lmagan o'pka saratoni (NSCLC) uchun; Rinatabart Sesutecan ni platina-rezistent tuxumdon saratoni va qattiq o'smalar uchun; GEN1059, GEN1055 va GEN1057 ni qattiq o'smalar uchun; va GEN1286 ni rivojlangan qattiq o'smalar uchun ishlab chiqmoqda. Bundan tashqari, kompaniya DARZALEX/DARZALEX FASPRO ni ko'p miyeloma (MM) va engil zanjirli amiloidoz uchun; RYBREVANT ni NSCLC uchun; TECVAYLI va TALVEY ni R/R MM uchun; Kesimpta ni takrorlanuvchi ko'p skleroz uchun; va TEPEZZA ni qalqonsimon bez kasalliklari uchun taklif etadi. Shuningdek, u Amivantamab ni takroriy/metastatik bosh va bo'yin saratoni, hamda rivojlangan yoki metastatik kolorektal saraton uchun; Amlenetug ni ko'p tizimli atrofiya uchun; Inclacumab ni sil kasalligi bilan bog'liq vazookklyuziv inqirozlar uchun; va Mim8 ni gemofiliya A uchun ishlab chiqmoqda. Kompaniya AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S va argenx bilan hamkorlik shartnomasiga ega. Genmab A/S 1998 yilda tashkil etilgan va shtab-kvartirasi Kopengagagen, Daniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
| Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director |
| Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
| Mr. Anthony Pagano CPA |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-17 | 6-K | gmab_20260617x6k.htm |
| 2026-06-16 | 6-K | gmab_20260616x6k.htm |
| 2026-06-15 | 6-K | gmab_20260615xx6k.htm |
| 2026-06-11 | 6-K | gmab_20260611xx6k.htm |
| 2026-05-29 | 6-K | gmab_29052026x6k.htm |
| 2026-05-13 | 6-K | gmab_20260513x6k.htm |
| 2026-05-12 | 6-K | gmab_20260512x6k.htm |
| 2026-05-08 | 6-K | gmab_20260508x6k.htm |
| 2026-05-07 | 6-K | gmab_20260507x6k.htm |
| 2026-04-17 | 6-K | gmab_2026417x6k.htm |
| Executive VP & CFO |
| Mr. Christopher Cozic | Executive VP & Chief People Officer |
| Mr. Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer |
| Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
| Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer |